Supporting Information

Palladium-catalyzed aminations of aryl halides with phosphine-functionalized imidazolium ligands

Ji-cheng Shi,^{1, †, ‡} Pengyu Yang,[‡] Qingsong Tong,[†] Li Jia[†]

College of Chemistry and Materials Science, Fujian Normal University, Fuzhou 350007, China, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, Liaoning E-mail: jchshi@fjnu.edu.cn

General procedure

All reactions and manipulations involving air- and/or moisture-sensitive compounds were carried out using standard Schlenk technique under nitrogen. NMR spectra were recorded on a BRUKER DRX 400 MHz or Varian INOVA 400 MHz (¹H 400 MHz; ¹³C 100 MHz; ³¹P 162 MHz) spectrometers. Chemical shifts are reported in ppm relative to TMS. Elemental analyses were obtained on an Elementar Vario EI analyzer. High-resolution mass spectra (HRMS, ESI) were obtained on a Micromass Q-Tof Micro (Micromass Inc., Manchester, England). GC analyses were performed on a BF-2002 spectrometer fitted with 50 m AT. SE-30 column. All amines, aryl bromides and chlorides (Aldrich or Acros) were used as received. Pd(OAc)₂, Pd₂(dba)₃ were purchased from Acros chemical Company. 1,4-Dioxane, toluene and THF were distilled from sodium benzophenone ketyl under nitrogen. Anhydrous DMF was freshly distilled from calcium hydride. KOH was ground to a fine powder using a mortar and a pestle and dried in a vacuum oven prior to use. Cs₂CO₃, K₂CO₃, KF, NaOBu', K₃PO₄ and NaOH were used as received.

General Procedure for Aminations of Aryl halides. *Representative Procedure*: An oven-dried round-bottom flask was cooled in vacuo, back-filled with nitrogen, and

¹ Corresponding author. E-mail: <u>jchshi@fjnu.edu.cn</u> (J.-c. Shi).

[†] Fujian Normal University.

[‡] Dalian Institute.

charged with Pd(OAc)₂, imidazolium salts, and NaO'Bu (were weighed in air). Then the flask was evacuated, and back-filled with nitrogen (three times), and dioxane was added under nitrogen. The mixture was stirred at 50 °C for 0.5 h. After cooling to room temperature, the aryl halide and amine were added, and placed in an oil bath. The reaction was monitored by TLC or GC. After complete consumption of starting materials, the reaction mixture was allowed to cool to room temperature, filtered through a layer of Celite with the aid of ethyl acetate. The filtrate was concentrated in vacuo and the crude product was purified chromatographically and the products were identified by ¹H NMR.

Cross-coupling products:

4-(4-Tolyl)morpholine² The general procedure afforded 170mg (96%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 2.87 (s, 4H), 3.71 (s, 3H), 3.86 (s, 4H), 6.84 (d, *J* = 7.6Hz, 2H), 7.09 (d, *J* = 8.0Hz, 2H).

4-(4-Methoxyphenyl)morpholine³ The general procedure afforded 172mg (89%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 3.00 (s, 4H), 3.71 (s, 3H), 3.80 (s, 4H), 6.78-6.80 (m, 4H).

N-[4-(trifluoromethyl)phenyl]morpholine⁴ The general procedure afforded 201mg (87%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 3.24 (t, *J* = 4.4Hz, 4H), 3.87 (t, *J* = 4.4Hz, 4H), 6.93 (d, *J* = 8.4Hz, 2H), 7.50 (d, *J* = 8.4Hz, 2H).

N-(2-Pyridyl)morpholine⁵ The general procedure afforded 154mg (94%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 3.46 (t, *J* = 5.2Hz, 4H), 3.78 (t, *J* = 4.8Hz, 4H), 6.59-6.64 (m, 2H), 7.44-7.48 (m, 1H), 8.18-8.19 (m, 1H).

N-(2-Methylphenyl)morpholine⁶ The general procedure afforded 165mg (93%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 2.30 (s, 3H), 2.88 (t, *J* = 4.8Hz, 4H), 3.82 (t, *J* = 4.8Hz, 4H), 6.98-7.01 (m, 2H), 7.14-7.18 (m, 2H).

N-(4-Methylphenyl)phenylamine⁵ The general procedure afforded 106mg (58%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 2.29 (s, 3H), 5.57 (br, 1H), 6.87 (t, *J* = 7.2Hz, 1H), 6.98-7.08 (m, 6H), 7.22 (t, *J* = 7.6Hz, 2H).

N-phenyl-morpholine⁷ The general procedure afforded 156mg (96%) of the title

compound. ¹H NMR (400 MHz, CDCl₃): δ 3.10 (t, *J* = 5.2Hz, 4H), 3.80 (t, *J* = 4.8Hz, 4H), 6.81-6.87 (m, 2H), 7.19-7.24 (m, 2H).

N-Hexyl-4-methylaniline⁷ The general procedure in argon afforded 159mg (83%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 0.90 (t, *J* = 6.4Hz, 3H), 1.26-1.42 (m, 6H), 1.60-1.66 (m, 2H), 2.10 (s, 3H), 3.12 (t, *J* = 7.2Hz, 2H), 6.58-6.64 (dd, *J*₁ = 7.8Hz, *J*₂ = 10.0Hz, 1H), 7.02 (d, *J* = 7.2Hz, 1H), 7.10 (t, *J* = 7.6Hz, 1H).

N,*N*-**Dibutyl-4-methylbenzenamine**⁷ The general procedure afforded 202mg (92%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 0.84 (t, *J* = 7.6Hz, 6H), 1.21-1.26 (m, 4H), 1.41-1.48 (m, 4H), 2.13 (s, 2H), 3.12 (t, *J* = 7.6Hz, 4H), 6.48 (d, *J* = 8.0Hz, 2H), 6.91 (d, *J* = 8.4Hz, 2H).

N-(2-Methoxyphenyl)morpholine⁷ The general procedure afforded 169mg (90%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 3.08 (s, 4H), 3.87-3.90 (m, 7H), 6.87-7.02 (m, 4H).

N-(4-Methylphenyl)piperidine⁷ The general procedure afforded 163mg (93%) of the title compound.

N-(2,6-Dimethylphenyl)morpholine⁷ The general procedure afforded 138mg (72%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 2.85 (d, *J* = 3.2Hz, 6H), 2.86 (t, *J* = 4.8Hz, 4H), 3.82 (t, *J* = 4.8Hz, 4H), 6.90-7.00 (m,3H).

N-Hexyl-2-methylaniline⁷ The general procedure afforded 170mg (89%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 0.87-0.91 (m, 3H), 1.26-1.43 (m, 6H), 1.58-1.65 (m, 2H), 3.23 (m, 2H), 4.6 (br, 1H), 6.36 (d, *J* = 8.4Hz, 1H), 6.54 (dd, *J*₁ = 1.2Hz, *J*₂ = 5.6Hz, 1H), 7.38-7.42 (m, 1H), 8.06 (d, *J* = 5.2Hz, 1H).

4-(4-Imidazol-1-yl-3,5-dimethylphenyl)morpholine The general procedure afforded 183mg (71%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 2.00 (s, 6H), 3.20 (t, *J* = 4.8 Hz, 4H), 3.87 (t, *J*=4.8Hz, 4H), 6.66 (s, 2H), 6.90 (s, 1H), 7.24 (s, 1H), 7.46 (s, 1H).

1-(4-Imidazol-1-yl-3,5-dimethylphenyl)-4-(3,5-dimethylphenyl)piperazine The general procedure afforded 344mg (78%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 1.97 (s, 12H), 3.35 (s, 8H), 6.69 (s, 4H), 6.87 (s, 2H), 7.21 (s, 2H), 7.43 (s, 2H).

1-(4-Imidazol-1-yl-3,5-dimethylphenyl)piperazine The general procedure afforded 151mg (59%) of the title compound. ¹H NMR (400 MHz, CDCl₃): 1.97 (s, 6H), 3.03 (t, *J* = 5.2Hz, 4H), 3.18 (t, *J* = 4.8Hz, 4H), 6.66 (s, 2H), 6.87 (s, 1H), 7.20 (s, 1H), 7.41 (s, 1H).

1,4-Di-p-tolyl-piperazine⁷ The general procedure afforded 234mg (88%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 2.28 (s, 6H), 3.29 (s, 8H), 6.91 (d, J = 8.4Hz, 4H).

References:

(1) Seo, H.; Kim, J. H.; Kim, B. Y.; Lee, H. J.; Son, S. U.; Chung, Y. K. Organometallics **2003**, *22*, 618-620.

- (2) Tsuji, Y.; Huh, K. T.; Ohsugi, Y.; Watanabe, Y. J. Org. Chem. 1985, 50, 1365-1370.
- (3) Old, D.W.; Wolfe, J.P.; Buchwald, S.L. J. Am. Chem. Soc., 1998, 120, 9722-9723.
- (4) Kamikawa, K.; Sugimoto, S.; Uemura, M. J. Org. Chem., 1998, 63, 8407-8410.
- (5) Barluenga, J.; Aznar, F.; Fernandez, M. Chem. Eur. J. 1997, 3, 1629-1637.
- (6) Desmarets, C.; Schneider, R.; Fort, Y. Tetrahedron Lett., 2000, 41, 2875-2879.
- (7) Wolfe, J. P.; Buchwald, S. L. J. Am. Chem. Soc. 1997, 119, 6054-6058.



шdd -120 -100 -80 -60 -40 pp8.92--20 0 $(\pm$ Fe PPh₂ Ľ 20 L1 40 6 0 Pulse Sequence: s2pul 80











.

.





udd

[experies]



udd

13C NMR (-1-36 in CDC13)





,

Electronic Supplementary Information for Dalton Transactions This journal is © The Royal Society of Chemistry 2007











•

.





















wdd



13C NMR (YP-01-11 in CDC13)

wdd





































Electronic Supplementary Information for Dalton Transactions This journal is © The Royal Society of Chemistry 2007

















bpm -500-400 -300 -200 -100 0 \$29°2 100200 Fe P-Ph Ph Pd Cl 3.0.0 CI 400 PHOSPHORUS OBSERVE py-051123 4N_051123-18 Pulse Sequence: s2pul 500 600











© The Royal Society of Chemistry 2007